Severe hypoglycaemia with cognitive dysfunction is 3 times more common in intensively, rather than conventionally, treated insulin-dependent diabetes mellitus (IDDM). To investigate the effect of diabetes control on higher brain function during acute hypoglycaemia, we studied one of the earliest detectable changes in cognitive function, i.e. the four-choice reaction time, and symptomatic and hormonal responses during euglycaemic and hypoglycaemic clamping in human subjects. There were no changes in symptoms or counterregulatory hormones and four-choice reaction time was stable during 220 min of euglycaemic insulin clamping in five men with IDDM, with a coefficient of variation of less than 2.2 % (1% for accuracy) for the cognitive function test. During stepped hypoglycaemic clamping however, hormonal responses and subjective awareness of hypoglycaemia occurred in all groups but started at much lower blood glucose concentrations in eight intensively-treated diabetic subjects (Group 1) than in ten conventionally-treated (Group 2) or in eight non-diabetic subjects (Group 3). For example, for adrenaline, plasma glucose thresholds were 2.7 _+ 0.2 vs 3.4 + 0.2 and 3.2 + 0.1 mmol/1, respectively, p < 0.05, Group 1 vs Groups 2 or 3 and for subjective awareness of hypoglycaemia 2.3 + 0.2 vs 3.0 _+ 0.1 and 3.2 + 0.1 mmol/1, p _< 0.003), as in previous studies. In contrast, deterioration in reaction time occurred at 3.2 + 0.3, 3.2 + 0.2 and 3.0 + 0.2 mmol/1, respectively (p = NS), thus occurring at higher glucose levels than subjective awareness in the intensively-treated subjects only. The altered hierarchy of responses to hypoglycaemia in well-controlled intensively-treated diabetes explains the increased risk of severe hypoglycaemia without warning seen in such patients. [Diabetologia (1995[Diabetologia ( ) 38: 1412[Diabetologia ( -1418 
the incidence of both asymptomatic [3] and severe [2, 4] hypoglycaemia.
Some of the mechanisms underlying the defective responses to hypoglycaemia in intensified insulin therapy are now understood. Such therapy can induce defects in the usual symptomatic neurohumoral responses to experimentally-induced hypoglycaemia. These include a reduction in the magnitude of the hormonal response to any given hypoglycaemic stimulus [5, 6] and a lowering of the plasma glucose level at which each response begins [6, 7] . It is suggested that the latter is due to an adaptation of the glucose sensing centres to preceding hypoglycaemia such that they are better able to maintain their metabolism and function during subsequent exposure to a Data are mean + SD low blood glucose level [8] [9] [10] . Because at least some of these centres are intra-cerebral [11, 12] , one might expect other brain areas to undergo similar adaptation. If these include the cerebral cortex, cognitive function should also be better preserved during hypoglycaemia in hypoglycaemia-accustomed patients with delayed onset of counterregulation.
Although there are some experimental data to support this hypothesis [13, 14] , there are also data that do not [15, 16] . Furthermore, the hypothesis is not consistent with the clinical picture since intensively-treated diabetic patients with delayed subjective awareness of hypoglycaemia are not protected from severe episodes. One of the difficulties in investigating this issue is the lack of a sensitive and appropriate test for cognitive function that can be reliably applied repeatedly during induced hypoglycaemia. Electrophysiological measures are either too sensitive [17] or too crude [15] and summation of results from tests of multiple brain functions are also relatively insensitive [18] .
To ascertain whether patients with intensivelytreated diabetes and hypoglycaemia unawareness have better preserved higher cerebral function during hypoglycaemia, we chose to use the "four choice reaction time" as a measure of cognitive function. This test measures the ability of a subject to perceive, interpret and make a co-ordinated response to a stimulus and as such measures a useful complex function [19, 20] . This is also one of the functional tests most sensitive to hypoglycaemia. For our studies, we first validated repeated measurements over time during euglycaemia. We then measured symptomatic and neurohumoral responses and fourchoice reaction time during controlled insulin-induced hypoglycaemia in IDDM patients with strict glycaemic control and hypoglycaemia unawareness, those with poorly-controlled diabetes and good hypoglycaemia awareness, and in non-diabetic subjects.
Subjects, materials and methods
Study one. The study was approved by the Lewisham and North Southwark Committee on Ethical Practice. Written informed consent was obtained from each subject before enrol-1413 ment. Five males with IDDM, aged 33 _+ 4 years, diabetes duration 12 + 3 years (Table 1) were admitted to the metabolic ward on the evening before the study. The subjects fasted from 22.30 hours onward. Two intravenous cannulae were placed using intradermal lignocaine as local anaesthetic, one for infusion of glucose and insulin into a large arm vein of the non-dominant hand, the other, for blood sampling, was placed retrogradely in a hand vein of the same arm. Subjects omitted their usual evening dose of intermediate or long-acting insulin and blood glucose was controlled through the night by means of an intravenous infusion of soluble insulin, adjusted according to hourly blood glucose measurements made at the bedside. All subjects therefore began the study in the morning with near-normal blood glucose concentrations and hypoglycaemia during the night was excluded.
In the morning, the hand carrying the sampling line was rested in a heated box (55-60 ~ to arterialize venous blood [21] and the subject was trained on the four-choice reaction time test [19, 20, 22] . In this test, the subject is presented with a computer screen divided into four quadrants. A computer-generated signal appears in one quadrant at a time and the subject has to clear it by pressing a corresponding button on an adapted keypad. Up to 500 signals are presented in 5 rain. The mean time of the reactions and the accuracy (the percentage of correct responses) are recorded. Training occurs over a maximum of five assessments and is recognised as stability in the timing and accuracy of the reaction.
At time -40 min, a primed continuous infusion of soluble insulin (prepared in a 4 % solution of autologous blood in 0.9 % saline) was started at a maintenance rate of 1.5 mU 9 kg-l min -I and run for 220 min. Blood glucose was maintained at 5 mmol/1 throughout by means of an infusion of 20 % glucose, adjusted according to blood glucose measurements made at the bedside at 5-to 10-rain intervals [23] . Every 20 min, a full set of data was collected: blood samples for later measurement of the hormones of glucose counterregulation, measurement of the fourchoice reaction time and completion of symptom scores.
Symptom scores were recorded by questionnaires in which 52 symptoms were ranked individually from 0 (absent) to 6 (very severe). Adrenergic symptom scores were calculated from the scores of sweating, anxiety, trembling, tingling, heart pounding and feeling hot, neuroglycopenic symptom scores from the scores for inability to concentrate, confusion, dizziness, irritability, blurred vision, tiredness and drowsiness [24] .
Study two. Subjects were recruited into three groups (Table 1) . Group 1 comprised eight IDDM patients with tight metabolic control (HbAI~ 7.7 _4-0.3 %) and with a history of hypoglycaemia unawareness, substantiated by the occurrence of at least three blood glucose readings of less than 3 retool/1 Without symptoms during 2 months of home blood glucose monitoring; Group 2 comprised ten patients with less well-controlled diabetes (HbA 1~ 10.1 + 0.2 %) and good hypoglycaemic awareness, and Group 3 were eight non-diabetic control subjects. For the subjects with diabetes, the number of severe hypoglycaemic episodes (i. e. those requiring external assistance) in the 4 months preceding the study had also been ascertained, with data collected every 2 weekS.
The diabetic subjects were rendered euglycaemic overnight as for Study One. The non-diabetic subjects presented in a fasted state on the morning of study. Once each subject had been cannulated and been trained on the equipment for measuring four-choice reaction time, the insulin and glucose infusions were begun as in Study One but for these subjects, euglycaemia was maintained for only 40 min (-40 to 0 min). Thereafter blood glucose was reduced step-wise over 220 min to a glucose nadir of 2 mmol/1, after which euglycaemia was restored for a further 40 min [25] . Each glucose plateau was reached over 15 to 20 min and maintained for at least 20 min, so that each step lasted 40 min in total, except the nadir, which was reached rapidly and held for a total of 20 min. Hormone measurements were made at 20, 30 and 40 min and symptom scores and four-choice reaction times recorded at 20 and 40 rain into each plateau. In the non-diabetic subjects, euglycaemia was maintained from time 0 to 40 rain, the first hypoglycaemic step was to 3.8 mmol/1 and hypogtycaemia was terminated at 2.6 mmol/1, time 180 min. At the end of any study, subjects received lunch (and subcutaneous insulin if they were diabetic). Glucose monitoring was continued until stable euglycaemia was maintained spontaneously, after which all intravenous lines were withdrawn. (2)) and non-diabetic subjects (A) lyzer, Yellow Springs Instruments, Yellow Springs, Ohio, USA). Catecholamines were measured by high performance liquid chromatography [26] and cortisol [27] , growth hormone [28] and free insulin concentrations [29] were measured by radioimmunoassay. Intra-assay variation for any assay was less than 10 %. Thresholds for hormone responses were taken as the blood glucose level at which a given hormone concentration exceeded the mean of the five baseline (euglycaemic) levels by more than two standard deviations on two or more consecutive samples. A significant rise in symptom score was taken as a rise of two points or more over the score at euglycaemia, again on at least two successive occasions. After completion of Study One, a significant deterioration in reaction time was considered to have occurred when there were two or more consecutive increments of 5 % or more and a loss of accuracy was defined as an increase of 2 % or more in error rate, with the last measure made during euglycaemia as the baseline. If a significant change did not occur during hypoglycaemia, the glucose nadir was entered as the threshold for the statistical analyses.
Measurements and calculations.

Statistical analysis
Demographic data are given as mean + SD; all other data are given as mean + SEM. Hormone responses (area under curve) and comparison of thresholds was made by one-way analysis of variance (ANOVA) and significance has been attributed to the groups by subsequent unpaired t-testing, except for growth hormone and cortisol data, available only for Groups One and Two, and so compared by unpaired t-testing alone.
Results
Study one.
Blood glucose level was maintained at 5.1 + 0.04 mmol/1 throughout, with a coefficient of variation of 4.6 + 1.3 % (mean + SD). There were no significant changes in symptom scores (maximum individual score + 1) or counterregulatory hormones. In the four-choice reaction time, the coefficient of variation for accuracy was 1% and for speed was 2.2 % (Fig.1.) . In Study Two, we therefore took a loss of accuracy of 2 % and/or an increase in speed of 5 % to indicate a significant deterioration in function.
Study two. Clinical monitoring before the clamp study in Groups i and 2 showed a similar frequency of mild hyp0glycaemia in the preceding 2 months (4 to 23 episodes per patient in Group 1 vs 0-15 in Group 2) but an increased frequency of severe hypoglycaemia in Group i (0-4 vs none, p < 0.04) in the preceding 4 months. Five of the Group 1 patients had experienced at least one severe hypoglycaemic episode within 6 months of the study. The blood glucose profiles for the clamps are shown in Figure 2 A. The hypoglycaemic profile was identical for the two groups of IDDM subjects. In the non-diabetic subjects, the profile was distorted by the initial euglycaemic phase but the rate of glucose fall was not significantly different from 80 to 180 min (0.0094 + 0.0006, 0.0099 + 0.0005 and 0.0106 + 0.0007 mmol/1 per rain, p = 0.23).
As shown in Figure 2B , the magnitude of the adrenaline responses was significantly reduced in the well-controlled hypoglycaemia-unaware diabetic group. Peak responses were lowest in Group 1 (1.28 + 0.26 nmol/1), significantly greater in Group 2 (2.63 + 0.24 nmol/1, p < 0.05) and highest in Group 3 (3.7 + 0.4 nmol/1, p < 0.05 against either of the other groups). The blood glucose concentration at which the adrenaline response began was significantly lower in Group 1 than in the other two groups (2.7 + 0.2 vs 3.4 + 0.2 and 3.2 + 0.1 mmol/1, p = 0.03, Group 1 vs Group 2 p < 0.02; vs Group 3, p < 0.04). Similar reductions were observed in the magnitude of the responses of noradrenaline, growth hormone and cortisol, with lowering of the blood glucose levels associated with the onset of their responses, although for growth hormone the differences did not achieve significance (Table 2 ). Neither diabetic group had a glucagon response.
The blood glucose concentration at which subjects first became aware of hypoglycaemia (giving a positive answer to the question 'do you feel low?' or for non-diabetic subjects 'do you feel different?') was significantly lower in Group 1 (2.3 + 0.2 mmol/1) than in either Group 2 (3.0+0.1, p=0.003) or Group 3 (3.2 + 0.1, p = 0.003 vs Group 1 but 0.21 vs Group 2) (Fig. 3A) . Autonomic and neuroglycopenic symptom scores also rose at significantly lower blood glucose concentrations in the hypoglycaemia-unaware patients in strict metabolic control (Group One) (Table 3) . In marked contrast, there were no significant differences in the blood glucose concentrations at which deterioration in performance of the four-choice reaction time was first observed, whether reaction time itself or accuracy of performance (Table 3) or deterioration in either (Fig. 3B) was considered. Only in Group One did cognitive function deteriorate before the onset of adrenaline or symptomatic responses (Fig. 2) . It is of interest that baseline reaction times were not different between the groups (473 + 30, 437 + 18 and 411 + 16 min, one-way ANOVA F = 1.79, p = 0.19).
Discussion
Intensified insulin therapy, aimed at maintaining long-term near-normoglycaemia in patients with IDDM, can reduce the risk of developing microvascular complications by up to 76 % [2] . However, such therapy has been associated with increased incidence both of loss of awareness of hypoglycaemia [3] and of severe hypoglycaemia, in which blood glucose falls so low that intellectual function and conscious level are impaired [2, 4] . The mechanism for this loss of awareness appears to be a lowering of the glucose level at which the symptomatic and hormonal responses to hypoglycaemia begin [6] and this is confirmed by our current data. In contrast, our data also show that the glucose level at which cognitive dysfunction first occurs is not lowered in such subjects. These data indicate a mechanism for both the asymptomatic hypoglycaemia and the increased risk of severe hypoglycaemia seen in patients on intensified insulin regimens, in whom the glucose level triggering symptomatic responses is significantly and uniquely lower than the glucose level at which cognitive dysfunction appears.
Although our findings are compatible with clinical experience of intensified insulin therapy, they may seem surprising in view of the evidence that both initiation of counterregulation and cognition are dependent upon brain metabolism. Onset of both can be delayed during hypoglycaemia by provision of physiological levels of non-glucose substrates for metabolism [30] [31] [32] , and animal studies localise the site of initiation of counterregulatory responses to the brain [11, 12] . In man, preceding hypoglycaemia can induce delayed and diminished symptomatic counterregulatory hormone responses to subsequent episodes acutely [8, 9] and cerebral glucose metabolic rate has been shown to be preserved during hypoglycaemia down to 2.4 mmol/1 after 56 h of moderate hypoglycaemia in healthy volunteers [10] . It has been suggested that the defective counterregulatory responses of hypoglycaemia unaware diabetic patients may result from a chronic adaptation of cerebral glu-A. Maran et al.: Cognitive dysfunction in acute hypoglycaemia cose sensing areas to recurrent hypoglycaemia, as a result of which they better maintain metabolic rate and function during subsequent episodes [32, 33] .
Delayed onset of symptomatic and counterregulatory responses should therefore be associated with delayed onset of cognitive dysfunction. This is not supported by our present findings or by data from earlier studies using the relatively insensitive cortical electroencephalogram (EEG) as an objective measure of cortical function [15] . However, some evidence for this association exists. There are reports of a lowering of the blood glucose level at which the latency of the P300 evoked potential (a measure of cortical processing) increases during hypoglycaemia in hypoglycaemia-accustomed intensively treated diabetic patients [13] and Fanelli et al. [14] described some delay (although less than that seen for symptom generation) in the onset of cognitive dysfunction measured by a battery of tests during hypoglycaemia in patients with short-term hypoglycaemia-unaware intensively-treated diabetes. Boyle et al. [10] described lowering of the glucose level at which performance in Stroop tests and finger tapping changed in normal volunteers made hypoglycaemic after 56 h exposure to a blood glucose level of 2.8 mmol/1. This is in direct contrast to our data.
One explanation for the discrepant results may be in the nature of the tests used to assess cognition. The P300 may be a very sensitive indicator of brain dysfunction, showing increased latency in one study (although not in others [34] ) at plasma glucose levels of 4 mmol/1, when there is no suggestion of clinically relevant cognitive impairment [35] . In contrast, a battery of cognitive function tests, applied at regular intervals during a hypoglycaemic challenge, may not be sufficiently specific, since the results of tests of several aspects of cortical function (some of which may be relatively insensitive to hypoglycaemia) are expressed as a single score. The battery method and indeed its component parts may also be relatively insensitive, changing in non-diabetic subjects at a glucose level of 2.4 mmol/1, with detectable deterioration in performance of digit span at 2.4 mmol/1, trail making at 2.3 mmol/1 and symbol digit modalities at 2.6 mmol/1 [33, 36] . When Widom and Simonson [9] compared the results of the elements of a cognitive function test battery individually, they found no effect of glycaemic control. The data from the Boyle study [10] are less readily compatible with ours, but the length and proximity of the antecedent hypoglycaemia may have produced a cortical effect not seen in response to the less stringent conditions of clinical diabetes treatment. Alternatively, different brain functions may be differentially affected. It is also possible that the tests are differently affected by catecholamines.
The four-choice reaction time, which requires signal perception and processing and the completion of a co-ordinated motor response, has been used to test higher brain function in such circumstances as recovery from anaesthesia [20] . We have shown it to be stable during repeated measurements at euglycaemia and it is not affected by catecholamines. It has the advantage of being quick to measure which is very important in studies of acute hypoglycaemia. As discussed above, our finding of a separation of effect of preceding glycaemic experience on cognition from that on counterregulatory responses may thus be due either to the increased sensitivity of the four-choice reaction time or to the fact that it is measuring a different aspect of cortical functioning from other tests.
The apparent inconsistency remaining between our data and those previously published is with the recent demonstration of preservation of cerebral glucose metabolism during hypoglycaemia in hypoglycaemia-accustomed healthy subjects [10] . This was an acute study in that measurements were made in healthy volunteers before and after 56 h of enforced moderate hypoglycaemia but it is likely to reflect the situation in hypoglycaemia accustomed IDDM patients. However, the arterio-venous difference technique used by Boyle et al. [10] to measure cerebral glucose utilisation rates measures glucose uptake by the whole intracranial contents. Our data would suggest that there is regional variation in the ease with which cerebral tissues can adapt to prior glycaemic experience to sustain their metabolism and function during subsequent hypoglycaemia. Such regional variation may also explain the apparent preservation of performance in Stroop testing and finger tapping seen in the study of Boyle et al. [10] . Confirmation of this requires more sophisticated techniques.
Heller and colleagues [37] first described a separation between the glucose levels required to trigger counterregulatory symptoms and adrenaline responses and those associated with cognitive dysfunction in individuals with diabetes. The new finding in the present data is the initial separation of subjects into those who are at high and those at low risk for severe hypoglycaemia and the subsequent demonstration of a different hierarchy of responses to acute hypoglycaemia.
Our findings have important clinical implications. It is the ability to make a co-ordinated response to stimuli that matters in human performance. Our data suggest that at least some higher brain functions cannot adapt to recurrent preceding hypoglycaemia. Lack of symptoms during biochemical hypoglycaemia should not therefore be interpreted to suggest that the cerebral cortex is functioning normally. We can find no evidence that intellectual function is better preserved during hypoglycaemia in intensivelytreated hypoglycaemia unaware patients. Intensified insulin therapy regimens should be tailored to avoid biochemical hypoglycaemia [38] , no matter how well the individual patient appears to tolerate them. 
